However, modulating tier 1 protein of ADGRF5 was suggestively associated with an increased risk of ovarian cancer (p‐value of inverse variance‐weighted method = 0.047) and breast cancer (p‐value of inverse variance‐weighted method = 0.042). Here, ADGRF5 is linked to breast cancer.